myocardium

[Immunopharmacology and Immunotoxicology] The authors revealed the function of bone marrow MSC-derived exosomes in sepsis-induced myocardial injury and the molecular mechanism.

[Stem Cell Research & Therapy] Umbilical cord (UC)-MSCs have few human leukocyte antigen-II and major histocompatibility complex class I molecules, and are easy to isolate and culture, UC-MSC sheets have been proposed as a candidate for clinical applications to ischemic heart disease.

[Seminars in Cell & Developmental Biology] In recent years, direct reprogramming of resident cardiac fibroblasts to induced cardiac-like myocytes has emerged as a promising therapeutic strategy to repurpose the fibrotic response of the injured heart toward a functional myocardium.

[NPJ Regenerative Medicine] Researchers demonstrated that cardiomyocyte proliferation greatly contributed to heart regeneration in adult Xenopus tropicalis upon apex resection.

[Idorsia Pharmaceuticals Ltd] Idorsia Pharmaceuticals Ltd announced the initiation of the Phase III registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y12 receptor antagonist, in suspected acute myocardial infarction.

[Heartseed, Inc.] Heartseed, Inc., a biotechnology company developing iPSC-derived cardiomyocytes for heart failure, announced it has raised approx. $37 Million at Series C round. These funds will accelerate the initiation of a global clinical trial of HS-001, an allogeneic iPSC-derived, highly purified ventricular cardiomyocyte spheroids for heart failure.